Revenue segments as reported by the company.

Women’s Health

Biosimilars

Established Brands

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Acquired in-process research and development and milestones

Interest expense

Exchange losses (gains)

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Organon & Co

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Organon & Co reports strong Q4 earnings, eyes growth opportunities

Organon & Co's Q4 2022 earnings call highlighted robust financial performance, strategic initiatives in key segments, and a positive outlook for future growth. Despite challenges in China and market dynamics, the company remains focused on leveraging its strengths, addressing challenges, and capitalizing on growth opportunities to drive shareholder value and portfolio expansion.

Organon & Co reports solid Q1 performance and eyes growth opportunities

Organon & Co's Q1 2023 performance reflects revenue growth, margin improvement, and strategic investments in key franchises and medical devices.
The company's strengths lie in financial discipline, strong segment performance, and growth opportunities in fertility markets and biosimilars.
Challenges include inflationary pressures, competitive pricing scenarios, and the need to address loss of exclusivity and pricing dynamics.
Opportunities exist in expanding market presence in Asia Pacific, launching new products, and focusing on sustainable growth through financial prudence.

Organon & Co reports solid Q2 earnings, eyes growth opportunities

Organon & Co's Q2 2023 performance showed revenue growth, margin improvement, and strategic focus on key business segments.
Strengths in product differentiation, market positioning, and growth drivers position the company for continued success.
Challenges in revenue drivers, market expansion, and financial strategy require strategic adjustments for sustained growth.
Opportunities in Women's Health, biosimilar portfolio, and market penetration strategies offer avenues for future growth and market leadership.

Organon reports mixed Q3 results, eyes biosimilar growth opportunities

Organon's Q3 performance showed mixed results with challenges in women's health and biosimilar uptake, but stable growth in established brands.
The company is focusing on cost efficiency, portfolio optimization, and market expansion in biosimilars for future revenue growth.
Despite near-term challenges, Organon remains optimistic about its financial outlook, especially with opportunities in biosimilars and market expansion strategies.
Strategic shifts towards retail sector in China and product optimization are key focus areas for sustained growth and profitability.

Organon & Co reports solid Q4 earnings, eyes strategic growth

Organon's Q4 2023 earnings call showcased strong financials, strategic partnerships, and a focus on cost management. The company aims for low single-digit revenue growth in 2024 and $1 billion in free cash flow.

Organon & Co reports strong Q1 performance, eyes biosimilar growth

Organon & Co's Q1 2024 showcased robust revenue growth and strategic financial planning
Challenges include flat global fertility business and cautious outlook due to foreign exchange dynamics
Opportunities lie in expanding biosimilar market, margin expansion, and transformative deals

Organon & Co reports solid Q2 earnings, eyes franchise growth

Organon & Co's Q2 2024 performance reflects a mix of solid revenue growth and margin stability.
While facing challenges in certain regions and franchise segments, the company maintains a focus on growth.
Strategic opportunities lie in expanding key franchises, regulatory milestones, and operational efficiency.
Overall, Organon & Co remains optimistic about sustained revenue growth and financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Organon was formed as a result of Big Pharma Merck's decision to spin out its Established Brands, Women's Health and Biosimilars divisions into a new entity. Shares began trading in May, and traded at $37 in early June, before sliding in response to Q121 earnings. Current price is $29.6.

Organon: Merck Spin-Off's Shares Hard To Resist At Current Price

Lordstown Motors

On the surface, these companies seem like underpriced investments, but look a little closer and there's a good reason to stay away.

3 Stocks I'd Avoid at All Costs

bluebird bio

Merck

Neither healthcare stock has performed well so far this year.

Should Investors Hold Out Hope for bluebird bio and Merck Spinoff Organon?

Organon's low growth, lack of strong catalysts and likely average future dividend combine to make OGN stock unattractive. The post Stay Away From Low-Growth Organon appeared first on InvestorPlace.

Stay Away From Low-Growth Organon

Cognyte Software

Vimeo

Some spinoffs can unlock the true value of businesses by allowing them to focus on their niches better than being part of a bulkier multi-faceted corporation allows. On the other hand, some spinoffs are made by the parent companies to shed dead weight, help get rid of legal liabilities or satisfy regulatory requirements in order to be cleared for a merger or acquisition.

Spinoffs Roundup: These Companies Could Unlock Value in 2021

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon Recommends Stockholders Reject Below-Market Mini-Tender Offer by TRC Capital Investment Corporation

Organon Recommends Stockholders Reject Below-Market Mini-Tender Offer by TRC Capital Investment Corporation

If a company's spun off from a pharmaceutical giant, you'd think the buzz about it would be deafening. Yet OGN stock remains an underappreciated gem.

Don't Miss the Opportunity Presented by Organon Stock

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon Announces Filing of Form 10-Q for the quarter ended March 31, 2021

Organon Announces Filing of Form 10-Q for the Quarter Ended March 31, 2021

Although spinoffs of well-known organizations have been known to outperform, you'll want to examine OGN stock carefully. The post Motivation Really Matters When It Comes to Organon appeared first on InvestorPlace.

Motivation Really Matters When It Comes to Organon

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon, A Global Women's Healthcare Company, Completes Acquisition of Alydia Health - A Medical Device Company Focused on Postpartum Hemorrhage

Organon Completes Acquisition of Alydia Health – A Medical Device Company Focused on Postpartum Hemorrhage

Alibaba

British American Tobacco

The market is trading at some of the most overvalued levels in 20 years. Over the next five years, analysts expect 5% CAGR returns from the S&P 500. That's about 1/3 of what investors have enjoyed for the last decade. But it's a market of stocks, not a stock market, and incredible bargains are always available.

3 Amazing Anti-Bubble Bargains That Could Triple In The Next 5 Years

Spinoffs can allow companies to showcase high-growth businesses. Organon, which Merck jettisoned this past week, could be another winner.

This Former Merck Company Could Have Big Potential

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Multimedia news release announcing the launch of Organon, a global healthcare company formed through a spinoff from Merck.

ADDING MULTIMEDIA Organon Launches as New Global Women's Health Company

LONDON--(BUSINESS WIRE)--Organon (NYSE: OGN) has today launched as the only global health company of its size, with a singular vision: to make a better and healthier every day for every woman. With a majority-female Leadership Team, the company will be headquartered in the US, with offices across the globe including one in Shoreditch, London. Organon has more than 60 products across an international footprint that will serve people in more than 140 countries, with nearly 80% of its approximatel

Organon Launches as New Women's Health Company

Organon Launches as New Global Women's Health Company

Lannett Company

S&P Global

NEW YORK, May 27, 2021 /PRNewswire/ -- Organon & Co. (NYSE: OGN) will be added to the S&P 500 prior to the open of trading on Thursday, June 3, replacing HollyFrontier, which will be removed from the S&P 500 effective prior to the open of trading on Friday, June 4. HollyFrontier will replace Service Properties Trust (NASD:SVC) in the S&P MidCap 400, and Service Properties Trust will replace Lannett Co Inc. (NYSE:LCI) in the S&P SmallCap 600 also effective prior to the open on June 4.

Organon Set to Join S&P 500; HollyFrontier to Join S&P MidCap 400; Service Properties Trust to Join S&P SmallCap 600

News for Organon & Co Stock (OGN)